Steady-state protein levels are determined by the balance between protein synthesis and degradation. Protein half-lives are determined primarily by degradation, and the major degradation pathways involve either lysosomal destruction or an ATPdependent process involving ubiquitination to target proteins to the proteosome. Studies have shown that multiple tumor-suppressor proteins are ubiquitinated and degraded by the 26S proteasome. In the present study, we investigated whether the tumor suppressor/ cytokine melanoma differentiation-associated gene-7/interleukin-24 gene (MDA-7/IL-24) protein is ubiquitinated and its degradation controlled by the proteasome. Treatment of ovarian (2008) and lung (H1299) tumor cells with adenoviral delivery of mda-7 (Ad-mda7) or Ad-mda7 plus the proteosome inhibitor MG132 showed that MDA-7 protein expression was dependent upon proteosome activity. Western blot and immunoprecipitation analyses verified that the MDA-7 protein was ubiquitinated and that ubiquitinated-MDA-7 levels were increased in MG132-treated cells. These results were confirmed using small interfering RNA (siRNA)-mediated knockdown of ubiquitin. Furthermore, ubiquitinated MDA-7 protein was degraded by the 26S proteasome, as MDA-7 accumulation was observed only when cells were treated with MG132 but not with lysosome or protease inhibitors. Inhibition of the catalytic b-5 subunit of the 20S proteasome using siRNA resulted in MDA-7 protein accumulation. Finally, treatment of tumor cells with Ad-mda7 plus the proteasome inhibitor bortezomib resulted in increased tumor cell killing. Our results show that MDA-7/IL-24 is ubiquitinated and degraded by the 26S proteasome. Furthermore, inhibition of MDA-7 degradation results in enhanced tumor killing, identifying a novel anticancer strategy.
Introduction
Posttranslational protein modifications regulate protein function and stability. 1, 2 Although myriad posttranslational mechanisms exist to regulate protein function in cells (for example, phosphorylation, acetylation, myristoylation, methylation, prenylation sumolyation), protein degradation is regulated primarily by the ubiquitin-proteosome pathway. 3, 4 Degradation of cellular proteins is essential to maintain normal homeostasis, and defects in protein degradation have been associated with multiple disorders, including muscle wasting, neuronal diseases (Alzheimer's, Parkinson's, Pick's disease) and genetic disorders (Von Hippel-Lindau syndrome, Angelman syndrome, Liddle's Syndrome). 4 Recent studies have shown that multiple cellular proteins including tumor-suppressor proteins (p53, Rb, PTEN, ARF) are ubiquitinated and degraded by the 26S proteasome. [5] [6] [7] [8] [9] In fact, one mechanism for cancer cell survival and resistance to therapy has been attributed to the rapid ubiquitination and degradation of the tumorsuppressor proteins. Therefore therapeutic approaches to inhibit protein ubiquitination and degradation are being developed to promote stabilization of tumor-suppressor proteins as an anticancer mechanism. 10, 11 The melanoma differentiation-associated gene-7/interleukin-24 gene (mda-7/IL-24) is a novel tumor-suppressor/cytokine gene that belongs to the IL-10 cytokine family. 12, 13 However, MDA-7 is unique among the IL-10 family as it exhibits potent tumor-suppressive activity against numerous human cancer cell lines. [12] [13] [14] [15] [16] [17] Adenoviral delivery of mda-7 (Ad-mda7) exhibits potent antitumor activity as monotherapy, and when combined with chemotherapy, radiotherapy or biologic therapies shows enhanced antitumor activity. [18] [19] [20] [21] [22] Systemic delivery of mda-7 using nanoparticles or adeno-associated virus has also demonstrated antitumor activity. 23, 24 Additionally, MDA-7 has been shown to exert potent antiangiogenic activity both in vitro and in vivo. 22, 24, 25 Results from these studies demonstrate the tumor suppressive function of the cytokine MDA-7. Furthermore, recent studies have demonstrated that MDA-7 protein undergoes posttranslational modification including phosphorylation and glycosylation, findings not reported for IL-10 or for related family members. 12, 13, 14, 16 Because MDA-7 functions and undergoes posttranslational modification as do other tumor-suppressor proteins, we sought to define the degradation pathway for MDA-7 and to determine whether the protein undergoes additional posttranslational modification. In the present study, we show that the MDA-7 protein is ubiquitinated and degraded by the 26S proteasome and that inhibition of ubiquitin-mediated MDA-7 protein degradation enhances tumor cell killing.
Materials and methods

Cells and cell culture
The human ovarian cancer cell line 2008 was generously provided by Stephen B Howell (University of California, San Diego, CA). The human H1299 lung tumor cell line was available in our laboratory.
14 Both cell lines were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum and 1% K-glutamine/antimycotic solution. The cells were grown at 37 1C in a humidified atmosphere containing 5% CO 2 .
Agents MG132 and calpain inhibitor (PD150606) were obtained from Calbiochem (La Jolla, CA). Cycloheximide and ammonium chloride were obtained from Sigma Chemical Co. (St Louis, MO). Bortezomib (Velcade; Millennium Pharmaceuticals, Boston, MA) was purchased from the Pharmacy of The University of Texas MD Anderson Cancer Center. MG132 (10 mM) and PD150606 (25 mM) were prepared in dimethyl sulfoxide. Bortezomib was dissolved in phosphate-buffered saline (PBS) at 5 mM as a stock solution.
Recombinant adenoviral vector
Adenoviral delivery of mda-7 vector was constructed and purified as previously reported. 14, 15 The transduction efficiencies for the cell lines were determined with an adenoviral vector carrying green fluorescent protein.
Transduction efficiency was 480% when cells were infected with 3000 viral particles (vp) per cell (data not shown). On the basis of these results, cells in all subsequent experiments were treated with Ad-mda7 at 3000 vp per cell.
Cell viability assay
The cells were seeded in six-well plates at a density of 2 Â 10 5 cells per well. After 24 h, the cells were either not treated or treated with Ad-mda7 (3000 vp per cell) in triplicate in serum-free medium. After 3 h of treatment, cells were replenished with complete medium containing 10% serum. Subsequently, bortezomib (0.01 mM) was added to cells that were either not treated or treated with Ad-mda7. Tumor cells that did not receive any treatment served as a negative control. Cells in each treatment group were plated in triplicate and cultured for 3 days. Cells were then trypsinized and resuspended in 0.5 ml of serumfree medium and subjected to a cell viability assay using Trypan blue (GIBCO BRL, Grand Island, NY) as previously described. 15 The number of dead cells were counted and expressed as percent dead cells over dead cells in untreated control cells. Experiments were repeated at least two times, and data from a representative experiment are shown.
Protein half-life assay
The protein half-life assay was conducted as previously described. 17 Briefly, tumor cells were seeded at a density of 3 Â 10 5 cells in six-well plates and incubated overnight at 37 1C The next day, the cells were infected with Admda7. At 48 h after infection, cycloheximide (10 mg ml
À1
) was added to the cells to inhibit nascent protein synthesis. Cells were harvested at 3, 6, 9, 12, 24 and 48 h after cycloheximide treatment; cell lysates were then prepared and analyzed for MDA-7 protein expression by western blot analysis as previously described. 14, 15 Protein band densities were subjected to semiquantitative analysis using Optimas software (Media Cybernetics, Silver Spring, MD), and the relative values were expressed in arbitrary units with control (time 0) set at an arbitrary value of 1.
17
In vitro ubiquitination assay Cells were grown in a six-well plates at a density of 3 Â 10 5 cells per well. At 24 h after incubation, cells were treated with MG132 (2 mg ml À1 ), Ad-mda7 (3000 vp per cell) or Ad-mda7 plus MG132. Cells that did not receive any treatment served as a control. After 24 h of treatment, cells were washed once with PBS and trypsinized, and whole-cell lysates were prepared. Cell lysates were subjected to western blot analysis and probed with antiubiquitin antibody (Santa Cruz Biotechnology, Santa Cruz, CA) and anti-MDA-7 antibody (Introgen Therapeutics Inc., Houston, TX).
For the immunoprecipitation assay, cells (1 Â 10 6 ) were plated in 10-cm tissue culture dishes and treated with PBS, Ad-mda7 (3000 and 7000 vp per cell) and Ad-mda7 plus MG132. After 48 h of treatment, the cells were collected and total cell lysates were prepared and subjected to immunoprecipitation. Briefly, total cell lysates containing 1 mg of cellular protein were mixed with antihuman MDA-7 antibody bound to protein Aconjugated agarose beads in 1.5-ml Eppendorf tubes and incubated overnight at 4 1C. The next day, the samples were spun in an Eppendorf microcentrifuge at 10 000 rpm for 5 min at room temperature. The upper supernatant was discarded, and the agarose beads were washed twice with PBS. The proteins were then eluted with sodium dodecyl sulfate (SDS) sample buffer for western blot analysis. Ubiquitinated MDA-7 protein was detected by western blotting, probed using anti-ubiquitin antibody and visualized on an enhanced chemiluminescence film (Hyperfilm, Amersham Biosciences, Piscataway, NJ) using the enhanced chemiluminiscence (ECL) western blot detection reagent (Amersham Biosciences) as previously described. 15, 17 The membranes were subsequently washed, restripped and reprobed for MDA-7 protein expression using anti-MDA-7 antibody.
In an identical but separate set of experiments, total cell lysates were immunoprecipitated using antihuman ubiquitin antibody and probed for MDA-7 protein. All other experimental and treatment conditions were the same as described above.
Assay of 26S proteasome activity
Proteasome activity assays were performed as previously described [21] . Briefly, cells were seeded in six-well plates (3 Â 10 5 cells per well) and treated with Ad-mda7, MG132 (5 mm) or Ad-mda7 plus MG132 (5 mm). After 24 h of the start of treatment, the cells were lysed in proteasome buffer (20 mM Tris-HCl (pH 7.2), 0.1 mM ethylenediaminetetraacetic acid (EDTA), 5 mM ATP, 10 mM dithiothreitol, 20% glycerol and 0.04% NP40), sonicated and then centrifuged at 1300 g at 4 1C for 10 min to remove insoluble material. The upper supernatant phase was collected, and the protein concentration of cell lysates was determined as previously described. 18 To assay the chymotrypsin-like activity of the proteasome, the fluorogenic substrate succinyl-leucyl-leucyl-valine-tyrosine-7-amino-4-methylcoumarin (Chemicon International, Inc., Temecula, CA) was used. Total protein (20 mg) from each treatment group described above was diluted to 100 ml in reaction buffer (25 mmol l À1 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (pH 7.5), 0.5 mmol l À1 EDTA, 0.05% NP40 and 0.001% SDS). Fluorogenic substrate was added to each sample, and the sample was incubated at 37 1C for 1 h. The intensity of fluorescence in each sample solution was measured using a fluorescence plate reader (Dynatech Laboratories, Chantily, VA) at 360 nm excitatory and 460 nm emission wavelengths. All readings were standardized using the fluorescence intensity of an equal volume of free 7-amino-4-methylcoumarin solution (50 mm). The results were expressed as the percentage of proteasome activity over the activity observed in untreated control cells.
Small interfering RNA assay
For experiments involving b-5-specific small interfering RNA (siRNA) of the 20S proteasome, cells (1 Â 10 5 per well) were plated in six-well plates. At 24 h after incubation, cells were washed, replenished with fresh medium and transfected with 200 nM of a b-5-specific siRNA or control siRNA (Dharmacon Inc., Lafayatte, CO) by using a siRNA transfection reagent (Dharmacon Inc.) as previously described. 17 After 24 h of siRNA transfection, cells were treated with Ad-mda7 (3000 vp per cell); cells were harvested 48 h later and an aliquot of the harvested cells was used to count the number of cells using the Trypan exclusion method. From the remaining harvested cells, cell lysates were prepared and analyzed for b-5 subunit and MDA-7 protein expression by western blot analysis. 15, 17 Cells that were untreated, treated with control siRNA alone or treated with b-5 siRNA alone served as controls.
For experiments involving ubiquitin-specific siRNA, cells were transfected with 100 nM ubiquitin-specific siRNA (Santa Cruz Biotechnology) using siRNA transfection reagent (Santa Cruz) for 24 h. Cells were subsequently washed, placed in fresh culture medium and either not treated or treated with Ad-mda7. Cells that did not receive any treatment served as control. After 48 h of Admda7 treatment, cells were washed, and cell lysates were prepared and subjected to the western blot analysis as described below.
Western blot analysis
Cells receiving different treatments were collected at the indicated times, and whole-cell lysates were prepared and subjected to western blotting as previously described. 14, 15, 17 The following primary antibodies were used for detection: ubiquitin (Santa Cruz Biotechnology), b5 subunit of 20S proteasome (BIOMOL International L.P., Plymouth Meeting, PA), caspase-9 and caspase-3 (Cell Signaling Technology, Beverly, CA); MDA-7 (Introgen Therapeutics Inc.) and b-actin (Sigma).
Statistical analysis
All of the in vitro experiments were performed at least two times, and the experimental results were analyzed for statistical significance with t-tests. The significance level was set at Po0.05.
Results and discussion
MDA-7 is rapidly degraded in situ
We first determined the stability of the mda-7 protein by conducting the protein half-life assay using 2008 cells. Western blot analyses of cell lysates collected from Admda7-treated tumor cells showed intense banding of MDA-7 protein (Figure 1 ). Multiple bands of MDA-7 protein representing different stages of glycosylation were observed and concurred with the results of previous reports.
12 -15 However, analysis of cell lysates collected from Ad-mda7-treated cells in the presence of cycloheximide showed a marked reduction in MDA-7 protein expression (Figure 1a) . More than 70% of the protein levels were decreased at 3 h after treatment with cycloheximide, and MDA-7 expression continued to decrease over time, with very low levels detected at 48 h (Figure 1b) . Extrapolation of the data showed the half-life of MDA-7 protein to be approximately about 1.8 h. Additionally, these results indicate that MDA-7 protein is degraded in an ordered manner and form the basis for the studies described below.
MDA-7 is ubiquitinated
The observation that MDA-7 protein is rapidly degraded led us to investigate whether the protein was ubiquitinated. Analysis of cell lysates for total ubiquitinated proteins from cells that were untreated, treated with MG132, treated with Ad-mda7 or treated with Ad-mda7 plus MG132 showed multiple intense bands representing detection of multiple ubiquitinated proteins (Figure 2a) . However, an increase in the intensity of the ubiquitinated proteins was observed only in cells that were treated with MG-132 or Ad-mda7 plus MG132, reflecting inhibition of the proteasome activity. Analysis of the same membrane for MDA-7 protein after restripping and reprobing with antihuman MDA-7 antibody showed MDA-7 protein expression only in cells that were treated with Ad-mda7 or with Ad-mda7 plus MG132 (Figure 2a) . However, the MDA-7 protein expression was markedly increased in cells treated with Ad-mda7 plus MG132 compared with the protein expression levels observed in cells treated with Ad-mda7. Additionally, the detection of multiple MDA-7 bands upon MG132 treatment indicated that the protein was polyubiquitinated, a phenomenon observed with other ubiquitinated proteins. 7, 26 Similar results were obtained when cell lysates from H1299 lung tumor cells were analyzed for ubiquitinated MDA-7 protein (Figure 2c ) and other tumor cell lines (data not shown) were analyzed for ubiquitinated MDA-7 protein.
The increased MDA-7 protein expression observed upon MG132 treatment was due to inhibition of the 26S proteasome activity was demonstrated by determining the proteasome activity in the cells. A significant reduction in proteasome activity was observed in cells treated with MG132 (60%) and Ad-mda7 plus MG132 (56%) compared with untreated cells or cells treated with Admda7 (Figure 2b ; Po0.05). Proteasome activity was not inhibited in Ad-mda7-treated cells compared with untreated cells. These results suggest that MDA-7 protein is ubiquitinated and that treatment with MG132 results in accumulation of ubiquitinated MDA-7 protein.
Confirmation that MDA-7 protein was being ubiquitinated was demonstrated by immunoprecipitation assays. Treatment of cells with Ad-mda7 at two different doses (3000 and 7000 vp per cell) showed a dose-dependent increase in the detection of ubiquitinated MDA-7 protein when pulled down using anti-MDA-7 antibody and detected with antihuman ubiquitin antibody (Figure 2d ; upper panel). Similarly, protein pulled down with antiubiquitin antibody followed by detection with anti-MDA-7 antibody showed a dose-dependent increase in detection of ubiquitinated MDA-7 protein (Figure 2d ; lower panel). In both methods, ubiquitinated MDA-7 proteins were detected between 17 and 25 kDa. The 25-kDa fraction of MDA-7 protein overlapped with the light chain of immunoglobulin G and hence could not be separately distinguished. However, the increase in the intensity of the 25-kDa band in Ad-mda7-treated cells compared with untreated control cells indicated the presence of ubiquitinated MDA-7 protein with a molecular mass of approximately 25 kDa.
Finally, siRNA-mediated knockdown of ubiquitin before Ad-mda7 treatment resulted in increased MDA-7 protein in Ad-mda7 plus ubiquitin siRNA-treated cells compared with findings for cells treated with Ad-mda7 alone (Figure 2e ). MDA-7 protein was not detected in cells that were untreated or in cells treated with ubiquitin siRNA alone. These results confirm that MDA-7 protein is ubiquitinated. However, the ubiquitin ligase responsible for ubiquitination of MDA-7 protein is not known and is currently under investigation in our laboratory.
MDA-7 is degraded by the 26S proteasome
Protein degradation is an inherent feature of cells to maintain normal homeostasis and prevent protein accumulation resulting in abnormal cellular function. Studies have shown that proteins can be degraded by the lysosome or by the 26S proteasome and to some extent by cellular proteases. 3, 27 We therefore used specific inhibitors to identify the mechanism by which MDA-7 protein was degraded. Should MDA-7 protein be degraded either by the lysosome or the proteasome, then the inhibition of their function using specific inhibitors should prevent protein degradation and result in increased levels of MDA-7 protein.
Treatment of Ad-mda7-infected cells with ammonium chloride (a lysosome inhibitor) or with PD150606 (a calpain inhibitor) showed no increase in MDA-7 protein expression compared with cells treated with Ad-mda7 alone (Figure 3a) . However, treatment of Ad-mda7-infected cells with MG132, a proteasome inhibitor, resulted in a marked increase in MDA-7 protein levels compared with the protein expression levels observed in To further confirm that MDA-7 protein degradation occurs by the 26S proteasome, siRNA studies were conducted. Studies have shown that the 20S catalytic unit of the 26S proteasome is the major component required for protein degradation and that this unit is composed of seven b subunits (b 1-b 7) . 3, 27 Of the seven b subunits, the b-5 subunit of the 20S proteasome has been shown to have the chymotryptic activity and to play an important role in the degradation of several ubiquitinated proteins. 27 Thus, inhibition of the b-5 subunit should result in reduced protein degradation. We therefore transfected cells with b-5-specific siRNA or with control siRNA. Cells were subsequently not treated or treated with Ad-mda7, and cell lysates were analyzed for MDA-7 protein expression at 48 h after Ad-mda7 treatment. As shown in Figure 3b , MDA-7 protein expression was detected in cells that were treated with Ad-mda7. However, MDA-7 protein expression was markedly higher in cells that were treated with b-5 siRNA and Ad-mda7 compared with cells treated with control siRNA and Ad-mda7 or treated with Ad-mda7 alone. Correlating with increased MDA-7 protein expression was the decrease in b-5 protein expression in cells treated with b-5 siRNA plus Ad-mda7, indicating that knockdown of b-5 expression results in MDA-7 protein accumulation. Additionally, reduced b-5 protein expression resulted in decreased proteasome activity in both cells treated with b-5 siRNA and those treated with b-5 plus Ad-mda7 (data not shown). A slight increase in MDA-7 protein expression was also observed in control siRNA plus Ad-mda 7-treated cells compared with Ad-mda7-treated cells. MDA-7 protein expression was not detected in cells that were untreated, treated with control siRNA or treated with b-5 siRNA (Figure 3b) .
To further examine whether increased MDA-7 protein expression as a result of b-5 downregulation showed any increased growth inhibitory effects, cells were subjected to a viability assay. Cells treated with control siRNA (8.5%), MDA/IL-24 ubiquitination and degradation by the proteasome B Gopalan et al b-5 siRNA (3.4%), Ad-mda7 (18.6), control siRNA plus Ad-mda7 (24.2%) and b-5 siRNA plus Ad-mda7 (40.6%) all showed an increase in the number of dead cells compared with untreated cells (Figure 3c) . However, the greatest increase in the number of dead cells was observed in cells treated with b-5 siRNA plus Ad-mda7 (40.2%) compared with all other treatment groups (o25% dead cells; Po0.05, Figure 3c ). These results show that ubiquitinated MDA-7 protein is degraded by the 26S proteasome and that the b-5 subunit of the 20S proteasome plays a role in MDA-7 protein degradation and its inhibition results in protein accumulation and enhanced tumor cell killing. These results also highlight MDA-7 as the first IL-10 family member to be shown to be ubiquitinated and regulated by the ubiquitin-proteasome pathway. Whether other members of the IL-10 family are similarly regulated by the ubiquitin-proteasome system is currently not known. Inhibition of MDA-7 degradation enhances tumor cell killing Previous studies have shown that inhibition of proteasome activity using MG132 or bortezomib results in enhanced tumor cell killing. 10, 11 Additionally, the combination of bortezomib with chemotherapeutic or biologic agents results in enhanced antitumor activity. 11, 28, 29 Because our studies showed that MDA-7 protein is ubiquitinated and degraded by the proteasome, we speculated that prevention of MDA-7 degradation with bortezomib, a proteasome inhibitor, would result in enhanced antitumor activity.
Treatment of 2008 tumor cells with Ad-mda7 plus bortezomib resulted in a significant increase in the number of dead cells (34%) compared with results for cells treated with Ad-mda7 (19.2%), or cells treated with bortezomib (8.2%; Po0.05, Figure 4a ). Molecular analyses of cell lysates showed increased MDA-7 protein levels in cells treated with Ad-mda7 plus bortezomib compared with Ad-mda7-treated cells. MDA-7 protein was not detected in untreated cells or bortezomib-treated cells (Figure 4b) . Activation of caspase-3, and caspase-9 was observed in cells treated with bortezomib, with Admda7 and with Ad-mda7 plus bortezomib but not in untreated control cells (Figure 4b) . However, activation of the caspase-9 and -3 was increased in cells treated with Ad-mda7 plus bortezomib compared with cells treated with bortezomib or Ad-mda7. These results demonstrate that treatment of these tumor cells with Ad-mda7 plus bortezomib leads to increased MDA-7 protein accumulation and cell killing.
Whether increased tumor killing observed in the present study is simply due to MDA-7 protein accumulation remains unclear. One possibility is increased intracellular MDA-7 protein levels leads to enhanced activation of cell-death signaling pathways that have previously been reported for mda-7-mediated killing. [14] [15] [16] [17] 20 Another possibility is the contribution by other proapoptotic proteins that are known to accumulate when treated with proteasome inhibitor. However, based on our results we believe increased tumor cell killing is likely due to the former and not the latter possibility as increased cell killing occurs only when Ad-mda7 was combined with the proteasome inhibitor. The molecular cell-death signaling pathway that is enhanced following combination treatment has not been investigated and is beyond the scope of the present study.
In conclusion, our results demonstrate for the first time the tumor suppressor/cytokine MDA-7/IL-24 protein is ubiquitinated and degraded by the 26S proteasome and that inhibition of its degradation using bortezomib enhanced antitumor activity. Our results provides basis for future preclinical studies testing the therapeutic effects of MDA-7/ IL-24 in combination with novel proteasome inhibitors or with inhibitors targeting the ubiquitin pathway. Figure 4 Inhibition of melanoma differentiation-associated gene-7 (MDA-7) degradation enhances tumor cell killing. Tumor cells were treated with adenoviral delivery of mda-7 (Ad-mda7), bortezomib or Ad-mda7 plus bortezomib and measured for cell viability by the Trypan blue exclusion method and for molecular markers by western blotting as described in the 'Materials and methods' section. (a) Treatment with Ad-mda7 plus bortezomib resulted in a marked increase in the number of dead cells (34%) compared with other treatment groups (o20%). Bars denote standard error. (b) Analyses for MDA-7 and apoptosis-associated molecular markers showed MDA-7 protein expression in cells treated with Ad-mda7 and cells treated with Ad-mda7 plus bortezomib; caspase-3 and caspase-9 cleavage was observed in cells treated with bortezomib, Ad-mda7 or Ad-mda7 plus bortezomib. b-Actin was used as loading control.
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